![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com/news-release/2024/07/25/2918728/0/en/Altimmune-Announces-Publication-of-Clinical-Study-of-Pemvidutide-in-Metabolic-Dysfunction-Associated-Steatotic-Liver-Disease-MASLD-in-Journal-of-Hepatology.html
https://www.fiercebiotech.com/biotech/altimmune-touts-best-class-lean-mass-results-weight-loss-therapy-quest-outdo-big-time
https://www.globenewswire.com/news-release/2024/06/23/2902705/0/en/Altimmune-Presents-Data-from-Phase-2-MOMENTUM-Trial-of-Pemvidutide-in-Obesity-during-Oral-Presentation-at-the-American-Diabetes-Association-s-84th-Scientific-Sessions.html
https://www.globenewswire.com/news-release/2024/06/18/2900298/0/en/Altimmune-Announces-Oral-Presentations-of-Pemvidutide-Clinical-Data-at-Upcoming-American-Diabetes-Association-s-Scientific-Sessions.html
https://www.globenewswire.com/news-release/2024/06/05/2893731/0/en/Altimmune-Presents-Data-at-EASL-International-Liver-Congress-2024-Supporting-the-Disease-Modifying-Potential-and-Differentiated-Therapeutic-Profile-of-Pemvidutide-in-Metabolic-Dysf.html
https://www.globenewswire.com/news-release/2024/05/29/2889737/0/en/Altimmune-to-Present-Clinical-Data-from-Pemvidutide-at-Upcoming-EASL-International-Liver-Congress-2024.html
https://www.globenewswire.com/news-release/2024/03/27/2853009/0/en/Altimmune-Announces-Positive-Lean-Mass-Preservation-Data-for-Pemvidutide-and-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/01/02/2802593/0/en/Altimmune-Announces-Presentation-of-Pemvidutide-Clinical-Data-at-Upcoming-NASH-TAG-Conference-on-January-6-2024.html
https://www.globenewswire.com//news-release/2023/11/30/2788970/0/en/Altimmune-Announces-Positive-Topline-Results-from-MOMENTUM-48-Week-Phase-2-Obesity-Trial-of-Pemvidutide.html
https://www.globenewswire.com//news-release/2023/10/26/2767385/0/en/Altimmune-Granted-Fast-Track-Designation-by-FDA-for-Pemvidutide-for-the-Treatment-of-Non-Alcoholic-Steatohepatitis-NASH.html
https://www.globenewswire.com//news-release/2023/10/25/2766393/0/en/Altimmune-to-Present-New-Data-on-the-Anti-Inflammatory-and-Anti-Fibrotic-Properties-of-Pemvidutide-in-a-Late-Breaking-Presentation-at-The-Liver-Meeting-2023.html
https://www.globenewswire.com//news-release/2023/09/26/2749354/0/en/Altimmune-Announces-Oral-Presentation-of-Pemvidutide-Clinical-Data-at-59th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html
https://www.globenewswire.com//news-release/2023/09/12/2741525/0/en/Altimmune-Announces-Completion-of-Dosing-in-the-Phase-2-MOMENTUM-Trial-of-Pemvidutide-in-Subjects-with-Obesity-or-Overweight.html
https://www.globenewswire.com/news-release/2023/08/01/2715690/0/en/Altimmune-Announces-Initiation-of-Phase-2b-IMPACT-Trial-Evaluating-the-Efficacy-and-Safety-of-Pemvidutide-in-Non-Alcoholic-Steatohepatitis-NASH.html